Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Vabysmo™ (faricimab-svoa) – New drug approval
January 28, 2022 - Genentech announced the FDA approval of Vabysmo (faricimab-svoa), for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
